Journal: Cancer Management and Research
Article Title: Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT
doi: 10.2147/CMAR.S215427
Figure Lengend Snippet: Identification of paclitaxel-resistant NSCLC cells. Notes: ( A ) Human NSCLC cells (H460_Parental and H460_TaxR) treated with indicated concentrations of paclitaxel for 72 h were subjected to cell viability assay. ( B, C ) H460_Parental and H460_TaxR cells were grown in triplicates in the absence or presence of indicated concentrations of paclitaxel for 2–3 weeks. The pictures and numbers of the cell colonies were obtained by the QuantiOne software of Fluor-S TM Multimager. ( D, E ) H460_Parental and H460_TaxR cells were treated with indicated concentrations of paclitaxel for 24 hrs. Cells were collected and subjected to Western blot analyses of PARP, Casp-3 or β-actin ( D ), or apoptotic-ELISA ( E ). Abbreviations: F-PARP, full length of poly(ADP-ribose) polymerase; C-PARP, cleaved PARP; Pro-Casp-3, Caspase-3; C-Casp-3, cleaved caspase-3; ELISA, enzyme-linked immunosorbent assay.
Article Snippet: After 2 weeks, cells were stained with 0.5% crystal violet (dissolved in 25% methanol) and clone number was quantified with QuantiOne software of Fluor-S TM Multimager (Bio-Rad Laboratories, Inc., Hercules, CA) at the end of the experiments.
Techniques: Viability Assay, Software, Western Blot, Enzyme-linked Immunosorbent Assay